Barclays on AstraZeneca (AZN): Acquisition of AMLN Makes Strategic Sense but High Price Tag
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Price: $92.77 --0%
Rating Summary:
19 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
19 Buy, 8 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on AstraZeneca (NYSE: AZN) price target of GBP31.50.
Analyst, Mark Purcell, said, "Joint pleasure and pain in winning Amylin (Nasdaq: AMLN) bid: Bristol-Myers Squibb (NYSE: BMY) and AZN team up to acquire Amylin for $31/share, AZN paying BMS $3.4bn to participate. The deal will be earnings dilutive for AZ in '12 and '13 and given the lack of cost synergy scope in the diabetes space appears to be an expensive investment in the potential of Amylin's Byetta/Bydureon ex-US, although any potential valuation dilution would seem limited to around 60p/share (2%) in the absence of any synergies at all."
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $44.75 yesterday.
Analyst, Mark Purcell, said, "Joint pleasure and pain in winning Amylin (Nasdaq: AMLN) bid: Bristol-Myers Squibb (NYSE: BMY) and AZN team up to acquire Amylin for $31/share, AZN paying BMS $3.4bn to participate. The deal will be earnings dilutive for AZ in '12 and '13 and given the lack of cost synergy scope in the diabetes space appears to be an expensive investment in the potential of Amylin's Byetta/Bydureon ex-US, although any potential valuation dilution would seem limited to around 60p/share (2%) in the absence of any synergies at all."
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $44.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Vivos Therapeutics posts 35% revenue gain but widens net loss
- SanDisk upgraded at JPMorgan after investor day; shares climb
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsRelated Entities
Barclays, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
